It is estimated that a staggering 1 in 10 people worldwide are living with kidney disease (1). Despite its high global prevalence and mortality, CKD has surprisingly often been overlooked on health agendas across the globe up until now. In particular, low and middle-income countries are disproportionately affected by CKD and kidney failure, with a […]
HealthLumen, in conjunction with AstraZeneca, have recently published a body of research from the “INSIDE CKD” programme, part of a major strategic initiative at AstraZeneca which is dedicated to changing the future for CKD patients. Our role is to support evidence-based policy making in CKD, which we do by harnessing the predictive power of microsimulation, […]
This week HealthLumen in partnership with AstraZeneca presented new work on the burden of chronic kidney disease (CKD) in the UK at the ERA-EDTA 2020 Congress. The study aims to compare and validate two different approaches to estimating the burden of CKD in the UK, and to estimate how this is predicted to change by […]
When you need a future-facing decision engine for big, real world population health questions, we are the people to turn to.
Solutions